Research programme: distamycin derivativesAlternative Names: Distamycin derivatives - research programme
Latest Information Update: 06 Sep 2002
At a glance
- Originator Nonindustrial source
- Mechanism of Action DNA inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 22 Nov 1999 New profile
- 22 Nov 1999 Preclinical development for Cancer in Italy (Unknown route)